Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery

References

• Turpie AG, et al. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med. 1986;315(15):925–929.
   PubMed Web of Science ®Google Scholar
• Jørgensen LN, Wille-Jørgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. BJS (British Journal of Surgery). 1993;80(6):689–704.
   PubMed Web of Science ®Google Scholar
• Hammond J, et al. Rates of venous thromboembolism among patients with major surgery for cancer. Ann Surg Oncol. 2011;18(12):3240–3247.
   PubMed Web of Science ®Google Scholar
• Merkow RP, et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg. 2011;254(1):131–137.
   PubMed Web of Science ®Google Scholar
• Huber O, et al. Postoperative pulmonary embolism after hospital discharge. An underestimated risk. Arch Surg. 1992;127(3):310–313.
   PubMedGoogle Scholar
• Edmonds MJ, et al. Evidence-based risk factors for postoperative deep vein thrombosis. ANZ J Surg. 2004;74(12):1082–1097.
   PubMed Web of Science ®Google Scholar
• Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51(2–3):70–78.
   PubMed Web of Science ®Google Scholar
• Caprini JA, et al. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17(Suppl 3):304–312.
   PubMed Web of Science ®Google Scholar
• Bahl V, et al. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg. 2010;251(2):344–350.
   PubMed Web of Science ®Google Scholar
• Rogers SO Jr., et al. Multivariable predictors of postoperative venous thromboembolic events after general and vascular surgery: results from the patient safety in surgery study. J Am Coll Surg. 2007;204(6):1211–1221.
   PubMed Web of Science ®Google Scholar
• White RH, et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998;158(14):1525–1531.
   PubMedGoogle Scholar
• Bergqvist D, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335(10):696–700.
   PubMed Web of Science ®Google Scholar
• Hull RD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001;135(10):858–869.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001;358(9275):9–15.
   PubMed Web of Science ®Google Scholar
• Lassen MR, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594–604.
   PubMed Web of Science ®Google Scholar
• Lassen MR, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807–815.
   PubMed Web of Science ®Google Scholar
• Lassen MR, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487–2498.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765–2775.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31–39. .
   PubMed Web of Science ®Google Scholar
• Lassen MR, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776–2786.
   PubMed Web of Science ®Google Scholar
• Turpie AG, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673–1680.
   PubMed Web of Science ®Google Scholar
• Neumann I, et al. Oral direct factor xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med. 2012;156(10):710–719.
   PubMed Web of Science ®Google Scholar
• Anderson DR, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158(11):800–806.
   PubMed Web of Science ®Google Scholar
• Anderson DR, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018;378(8):699–707.
   PubMed Web of Science ®Google Scholar
• Anderson DR, et al. American society of hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019;3(23):3898–3944.
   PubMed Web of Science ®Google Scholar
• Chapelle C, et al. Prevention of venous thromboembolic events with low-molecular-weight heparin in the non-major orthopaedic setting: meta-analysis of randomized controlled trials. Arthroscopy. 2014;30(8):987–996.
   PubMed Web of Science ®Google Scholar
• Van Adrichem RA, et al. Thromboprophylaxis after knee arthroscopy and lower-leg casting. N Engl J Med. 2016;376(6):515–525.
   PubMed Web of Science ®Google Scholar
• Samama CM, et al. Rivaroxaban or enoxaparin in nonmajor orthopedic surgery. N Engl J Med. 2020;382(20):1916–1925.
   PubMed Web of Science ®Google Scholar
• Afshari A, et al. European guidelines on perioperative venous thromboembolism prophylaxis: executive summary. Eur J Anaesthesiol. 2018;35(2):77–83.
   PubMed Web of Science ®Google Scholar
• Samama CM, et al. [French society of anaesthesia and intensive care. Guidelines on perioperative venous thromboembolism prophylaxis. Update 2011. short text. Ann Fr Anesth Reanim. 2011;30(12):947–951.
   PubMedGoogle Scholar
• National Guideline C. National Institute for Health and Care Excellence: clinical Guidelines, in Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. London: National Institute for Health and Care Excellence (UK)Copyright © NICE 2018.; 2018.
   Google Scholar
• Falck-Ytter Y, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e278S–e325S.
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997;84(8):1099–1103.
   PubMed Web of Science ®Google Scholar
• Matar CF, et al. Anticoagulation for perioperative thromboprophylaxis in people with cancer. Cochrane Database Syst Rev. 2018(7). doi:10.1002/14651858.CD009447.pub3.
   Web of Science ®Google Scholar
• Zaghiyan KN, et al. Timing of chemical thromboprophylaxis and deep vein thrombosis in major colorectal surgery: a randomized clinical trial. Ann Surg. 2016;264(4):632–639. .
   PubMed Web of Science ®Google Scholar
• Bergqvist D, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975–980. .
   PubMed Web of Science ®Google Scholar
• Vedovati MC, et al. A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg. 2014;259(4):665–669.
   PubMed Web of Science ®Google Scholar
• Felder S, et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 2019(3). doi:10.1002/14651858.CD004318.pub5.
   Web of Science ®Google Scholar
• Key NS, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520.
   PubMed Web of Science ®Google Scholar
• Farge D, et al. international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566–e581. 2019.
   PubMed Web of Science ®Google Scholar
• Gould MK, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e227S–e277S.
   PubMed Web of Science ®Google Scholar